The Israel Cancer Research Fund (ICRF) is proud to be an official charity partner of the 2026 United Airlines New York City Half Marathon.

Together, we are fundraising to support groundbreaking cancer research conducted by the best and brightest scientists at leading institutions throughout Israel, with a team goal of $36,000. Our goal is to end the suffering caused by cancer.

ICRF invests in the most promising Israeli scientists to advance ways to prevent, diagnose and treat cancer. As we celebrated our 50th anniversary, ICRF has funded nearly 3,000 grants totaling more than $100 million to scientists at leading Israeli institutions. In the current funding year, ICRF is supporting 76 promising cancer research projects, making us the largest nongovernmental funder of cancer research in Israel.

Thanks to the generosity of partners like you, ICRF is driving major breakthroughs in cancer science. ICRF-funded scientists have been instrumental in the development of breakthrough FDA-approved drugs Gleevec®, Doxil® and Velcade® and include the first two Israeli Nobel Prize Laureates in Chemistry. ICRF grantees continue to be at the forefront of cancer discoveries in nanomedicine, immunotherapy, stem cell research and targeted therapies.

We are truly grateful we have friends like you who are supporting ICRF today, so that our funded scientists can find tomorrow’s cures.

The answer to cancer is research! 

To learn more about our mission and work, please visit ICRFONLINE.ORG.